Hikma Pharma tumbles on softer guidance as buyback fails to soften pill

Hikma reported FY25 revenue up 7% to £3.3bn while operating profit fell 11% to £542m, with Injectables revenue +7%, Generics flat and Branded +10%. Management announced a $250m buyback and senior leadership changes, but FY26 guidance disappointed: group revenue growth guided to 2–4% (vs. consensus 5.6%), Injectables growth only in low single digits and Injectables EBIT margin cut to 27–28% (vs. consensus ~30.5%), and prior mid‑term guidance withdrawn—news that sent the shares down ~16% and prompted analysts to flag likely consensus downgrades.

Analysis

Market structure: Hikma (HIK.L) guidance miss shifts near-term winners to larger, diversified injectables and hospital-supply players (e.g., Baxter BAX, Novartis NVS/Sandoz) that can sustain pricing or capture tenders; specialist low-cost generic producers may also gain share. The guidance cut implies weaker demand or margin mix shift in Injectables (EBIT margin guided to 27–28% vs consensus ~30.5%), signaling price or cost pressure that will compress sector multiples near-term and raise credit spreads for mid‑cap pharma names.

Risk assessment: Tail risks include a major product recall, loss of a North American tender, or a large impairment tied to withdrawn mid‑term guidance — each could erase >20% equity value and widen Hikma CDS materially. Immediate effect (days–weeks) is elevated equity and IV volatility; short term (3–6 months) expect 5–15% consensus downgrades and margin rebaselining; long term (>12 months) outcome depends on management execution, CFO hire (catalyst within ~90 days) and buyback execution.

Trade implications: Favor short/option downside on HIK.L while rotating into deep‑pocket pharma; structured trades include limited‑risk put spreads to capture elevated IV and outright short equity for directional exposure. Pair trades (short HIK.L, long NVS or BAX) isolate company-specific guidance risk; sector rotation into larger cap pharma reduces idiosyncratic margin risk.

Contrarian angles: The market may over-penalize a single-year trough — the $250m buyback (~£200m at 0.8 FX, roughly 37% of 2025 operating profit) signals cash generation and board conviction and could underpin a mean-reversion if 2026 proves temporary. If HIK.L falls beneath 1,100p on continued fear (rather than structural loss), selective accumulation ahead of a stabilized margin trajectory and a completed buyback offers asymmetric upside in 6–12 months.

Key Decisions for Investors

• Establish a short position in HIK.L sized 4% of portfolio value (or equivalent delta exposure) within 1–3 trading days; target 1,000p in 3–6 months (≈28% downside from 1,390p) with a stop-loss at 10% above entry (~1,529p).
• Buy a limited‑risk Jun‑2026 HIK.L put spread (long 1,300p / short 1,000p) sized to risk no more than 0.75% of portfolio; close on move to ≤1,000p or if company announces positive near‑term catalysts (CFO appointment or >50% of $250m buyback executed) within 90 days.
• Execute a pair trade: short HIK.L (2–3% weight) and long Novartis (NVS) or Baxter (BAX) (3% weight) to capture idiosyncratic downside while benefiting from rotation into larger-cap injectables over 3–6 months; reassess on Q1 2026 trading updates.
• Prepare to accumulate HIK.L long (2–3% position) only if price breaches ≤1,100p OR management delivers concrete margin remediation/CFO hire within 90 days; target exit 9–12 months at ≥1,600p (≈45% upside from 1,100p) or on clear structural recovery signs.